IntegriChain Acquires the Life Sciences Division of Cumberland, Creating the Largest Data and Business Process Platform for Market Access and Commercialization of Specialty, Precision, and Retail Pharmaceuticals
Transaction Expands Customer Base to 220+ Life Sciences Manufacturers, including 20 of Top 20, and Team to 350+
Philadelphia, PA, April 13, 2020 – IntegriChain, a leading Life Sciences data and managed services company that helps drive access to life-saving and life-changing medicines, today announced that it has acquired Cumberland’s Life Science Division, a leading provider of managed services, advisory services and systems integration for contracts, pricing and revenue management. With this acquisition, IntegriChain delivers the Life Science industry’s most comprehensive and scalable data and business process platform for commercialization and market access of cell and gene therapy, specialty, and retail pharmaceuticals.
“This acquisition reinforces IntegriChain’s market-leading position to help manufacturers drive access and maximize their commercialization success throughout the brand life cycle, from pre-launch through growth,” said IntegriChain Co-Founder and CEO Kevin Leininger. “We now deliver the industry’s first and only data and managed services platform that unifies all of the critical business functions for commercialization and market access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider and pharmacy insights for our customers. As a result of this transaction, we are uniquely positioned to address critical therapy access challenges and ensure patients have access to specialty and precision medicines. We welcome all Cumberland Life Science consultants and professionals to our expanding global team as we continue to partner with our extensive combined customer base of more than 220 life sciences manufacturers to solve their access challenges.”